In this context, most of the studies that evaluated the effects of TF+ EVs on cancer-associated thrombosis employing mouse models were performed using pancreatic cancer cells [31,33], as this cancer type presents the highest incidence of VTE in cancer patients [1]. The gene discussed is TF; the disease is deep vein thrombosis.